Else Nutrition Completes Successful Commercial Trial Manufacturing Run of Ready to Drink Plant-Based Toddler & Kids Nutrition Products
Else Nutrition Holdings Inc. has announced the successful completion of a full-scale commercial trial for its ready-to-drink Plant-Based Complete Nutrition for Toddlers and Kids products. This achievement positions the company to tap into the $1 billion U.S. Kids Nutrition Drinks market and the $4 billion Infant Formula market, pending FDA approval. CEO Hamutal Yitzhak emphasized the opportunity to offer clean label, whole food-based products in accessible formats, enhancing Else's competitive advantage and establishing a crucial presence in hospitals for infant nutrition.
- Successful completion of full-scale commercial trial for RTD nutrition products.
- Access to a $1 billion U.S. Kids Nutrition Drinks market and a $4 billion Infant Formula market upon FDA approval.
- Ability to penetrate hospitals with plant-based liquid formula alternatives.
- None.
Capability Opens Up Major Growth Pathways including the
VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) ("Else" or the "Company") the plant-based baby, toddler and children nutrition company, announces that after months of R&D and trials, it has successfully completed a full-scale commercial trial manufacturing run of ready to drink (RTD) liquid version of its Plant-Based Complete Nutrition for Toddlers and Kids products.
“This key milestone sets the Company on a path to penetrate the lucrative liquid format in both the Toddler and Kids Nutrition space,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “With thousands of families nationwide already using Else products in powder format, being able to offer Clean Label, whole food-based Else products in convenient RTD form, opens up a further
Else intends to further use this capability to drive growth in the Kids and Toddler RTD markets across many geographies and sets the stage for being able to offer its planned infant formula in liquid format, upon receipt of FDA approval. The capacity to offer Else products in liquid format further enables the brand to penetrate hospitals with a long-awaited, Plant-Based liquid formula alternative, therein creating a critical competitive advantage for the Else brand. The hospital channel is of paramount importance in a parent/caregivers’ decision-making process when it comes choosing a formula for their baby/child.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
Media Contact
Erin Jundef
Brilliant PR
erinj@brilliantpr.com
For more information, contact:
Mrs. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: hamutaly@elsenutrition.com
P: +972(0)3-6445095
Mr. Sokhie Puar, Director of Else Nutrition
E: sokhiep@elsenutrition.com
P: 604-603-7787
US Investor Relations Contact
Lytham Partners, LLC
Mr. Ben Shamsian
New York | Phoenix
E: shamsian@lythampartners.com
P : 646-829-9701
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What recent milestone did Else Nutrition Holdings Inc. achieve?
How much is the U.S. Kids Nutrition Drinks market worth?
What potential markets could Else Nutrition enter upon FDA approval?
How does Else Nutrition plan to use its new RTD products?
